News | September 20, 2013

New York Proton Consortium Expands Access To Proton Therapy Through Agreement With Procure Proton Therapy Center In New Jersey

The New York Proton Center (NYPC), a consortium of five leading hospitals in New York City, including Continuum Health Partners, Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, the Mount Sinai Medical Center, and New York University Langone Medical Center, announced an agreement with ProCure Proton Therapy Center in Somerset, N.J., CentraState Health Care System, Princeton Radiation Oncology  and management services for NYPC being provided by 21st Century Oncology, a national provider of advanced radiation oncology services. This agreement will give the consortium’s patients access to a state-of-the-art proton treatment center in Somerset, N.J., one of only twelve such centers in the nation and the only center in the New York and New Jersey region. Proton therapy is a unique form of precision radiation that directly attacks tumors while minimizing potentially damaging radiation to surrounding healthy tissues and organs.

The NYPC consortium noted in a brief statement that they are "deeply committed to providing the highest standard of care to cancer patients, which includes access to proton therapy. For certain patients, especially those with solid tumors surrounded by sensitive tissue and vital organs, proton therapy is often the treatment of choice."   

Studies have shown proton therapy to be effective in treating many types of tumors, including pediatric cancers and selected tumors of the head and neck, brain, spinalcord, breast, gastrointestinal system, lung and prostate.

Unlike traditional X-ray beams that deposit a dose of radiation all the way through the patient’s body, proton beams stop abruptly and do not deliver radiation dose beyond the tumor.  In many cases, this unique property of protons allows physicians to concentrate radiation within the tumor while reducing the dose to surrounding tissues with greater precision than can be achieved with conventional radiation beams, thereby reducing the risk of side effects and improving the patient’s quality of life.  

Recognizing these benefits of proton therapy for patients with specific tumor types, NYPC’s agreement with the ProCure Proton Therapy Center allows this therapy to be conveniently accessible for their patients. Under the agreement, patients receiving care at NYPC hospitals who need proton therapy will continue to have their treatments provided by their physicians who will now have treatment privileges at the Proton Center.

“It has always been the Mission of ProCure and our affiliate CentraState Healthcare System to make proton therapy available to as many patients as possible,” said Oren Cahlon, M.D., of Princeton Radiation Oncology, medical director of the ProCure Proton Therapy Center in Somerset, N.J. “Our agreement with NYPC allows us to share our access to proton therapy and takes us one step closer to fulfilling our mission.”

The ProCure Proton Therapy Center in Somerset, N.J., in affiliation with CentraState Healthcare System and Princeton Radiation Oncology, opened in March 2012.

For more information: www.procure.com

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers. #ASTRO18 #ASTRO2018

A model of the new, compact, single-room Varian ProBeam 360 system. The system is an example of the trend in proton therapy toward single-room, smaller systems and away from multi-room treatment centers.

Feature | Proton Therapy | November 01, 2018 | Dave Fornell, Editor
A few of the big takeaways from the American Societ...
Victoria Advisory Committee for Proton Therapy Launched at ASTRO 2018
News | Proton Therapy | October 29, 2018
At the 2018 American Society for Radiation Oncology (ASTRO) annual meeting, IBA announced the launch of the Victoria...
Beaumont Hospital Cancer Institute Performs First Irradiation of Spot Scanning Proton Arc Therapy Plan
News | Proton Therapy | October 25, 2018
IBA announced the first irradiation of a Spot Scanning Proton Arc (SPArc) plan at the Beaumont Health Proton Therapy...
Varian Introduces New ProBeam 360° Proton Therapy System
News | Proton Therapy | October 23, 2018
Varian announced its new single-room proton therapy system, ProBeam 360°, at the 2018 American Society of Radiation...
Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018.

Feature | Stereotactic Body Radiation Therapy (SBRT) | October 23, 2018 | By Greg Freiherr
With its shorter course of treatment,...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t
Feature | Proton Therapy | October 04, 2018 | By Adam Conner-Simons
Investigating inside the human body often requires cutting open a patient or swallowing long tubes with built-in...